This site is intended for healthcare professionals

account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Results

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The main results of the IFNB Multiple Sclerosis Study Group trial were:

  • the high dose of interferon beta-1b resulted in a significant reduction in disease burden on MRI scans as compared to placebo

  • the annual relapse rate was significantly lower in the treatment arms:
    • 1.12 in the placebo group
    • 0.96 in the 1.6 MIU group
    • 0.78 in the 8 MIU group
    • the relapse rate was lower in patients on treatment who did not develop neutralising antibodies to interferon beta-1b

  • the was a non-significant reduction in confirmed progression of disability in the treatment arm

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page